Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026
Rhea-AI Summary
Ascentage Pharma (NASDAQ: AAPG) will release its full year 2025 unaudited financial results and provide business updates on March 25, 2026 (7:00 pm EDT) / March 26, 2026 (HKT). The company will host investor webcasts in English and Chinese with live Q&A and a replay available for the English presentation.
Analysts and investors must register in advance to access the respective language webcasts; timings: Chinese webcast at 10:00 pm EDT on March 25, 2026, and English webcast at 8:00 am EDT on March 26, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – AAPG
On the day this news was published, AAPG declined 1.10%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AAPG is up 3.38% with mixed peer moves: MIRM +3.27%, ZLAB +0.26%, ACAD +0.13%, while ACLX -0.10% and ARWR -1.30%. This points to a stock-specific move rather than a coordinated biotech sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Conference participation | Neutral | +0.3% | Management participation in three upcoming investor conferences and related webcasts. |
| Feb 09 | Conference appearance | Neutral | -3.7% | Announcement of fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026. |
| Feb 05 | China IND clearance | Positive | +1.4% | China CDE IND clearance for BTK degrader APG-3288 and plan for Phase I study. |
| Jan 14 | Strategy update | Positive | -3.6% | 2026 global innovation strategy and Phase III pipeline overview at J.P. Morgan conference. |
| Jan 06 | U.S. IND clearance | Positive | +8.5% | U.S. FDA IND clearance for APG-3288 enabling global Phase I study in B-cell cancers. |
Regulatory and pipeline milestones have often led to positive reactions, while broader strategy or conference updates have seen more mixed or negative trading.
Over recent months, Ascentage Pharma has focused on investor visibility and pipeline expansion. Multiple 6-K filings and press releases highlighted conference participation, U.S. and China IND clearances for BTK degrader APG-3288, and a 2026 innovation strategy centered on hematology drugs Olverembatinib and Lisaftoclax. Market reactions ranged from a +8.5% move on U.S. IND clearance to declines after strategy presentations, suggesting investors have been more responsive to concrete clinical/regulatory milestones than to general strategic or conference updates. Today’s earnings-date notice fits the pattern of neutral, informational disclosures.
Market Pulse Summary
This announcement sets the date and time for Ascentage Pharma’s unaudited full-year 2025 results and business updates, including separate Chinese and English webcasts. It follows a series of recent clinical and regulatory milestones, such as BTK degrader APG-3288 IND clearances and a 2026 innovation strategy centered on hematology assets. Investors may focus on upcoming revenue trends, progress in global Phase III programs, and commercialization updates for Olverembatinib and Lisaftoclax.
AI-generated analysis. Not financial advice.
ROCKVILLE, Md. and SUZHOU, China, March 11, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred herein as “Ascentage Pharma,” the “Company,” “we,” “us” or “our”), a global, commercial stage, integrated biopharmaceutical company engaged in discovering, developing and commercializing novel, differentiated therapies to address unmet medical needs in cancer, today reported it will release its full year 2025 unaudited results and provide business updates at 7:00 pm Eastern Daylight Time (EDT) on March 25, 2026 / 7:00 am Hong Kong Time (HKT) on March 26, 2026.
Analysts and investors are invited to join the investor webcast with Q&A, conducted by the Company’s management team.
Ascentage Pharma will host a Chinese (Mandarin) language investor webcast at 10:00 pm EDT on March 25, 2026 / 10:00 am HKT on March 26, 2026. To access the Chinese language investor event or conference call, please register in advance here.
The English language investor webcast will be held at 8:00 am EDT / 8:00 pm HKT on March 26, 2026. To access the English language webcast, please register in advance here. The webcast replay for English language presentation will also be available on the News & Events page of the Ascentage Pharma website.
About Ascentage Pharma
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors.
The Company’s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.
The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information
Investor Relations:
Yuly Chen, Senior Director of Investor Relations
Ascentage Pharma
Yuly.Chen@ascentage.com
+86 512 85557777
+1 (301) 792-565
Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282
Media Relations:
Sean Leous
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 866-4012
FAQ
When will Ascentage Pharma (AAPG) release its full year 2025 unaudited results and business updates?
What are the webcast times for Ascentage Pharma (AAPG) investor events on March 25–26, 2026?
How can investors access the Ascentage Pharma (AAPG) English language webcast and replay?
Is there a Mandarin-language investor webcast for Ascentage Pharma (AAPG) and how do I register?
Will Ascentage Pharma (AAPG) management be available for Q&A during the March 2026 webcast?
